Trial of the Technigas Plus Generator at Pirogov City Clinical Hospital No. 1
The Technigas Era Has Begun in Russia
Technigas was officially registered as a medical device back in 2020, but its introduction to the Russian market faced certain challenges.
In 2024, Technigas was adopted for trial use by Pirogov City Clinical Hospital No. 1, where it was used to diagnose 40 patients. This innovative method enabled the identification of reversible causes of pulmonary hypertension at the outpatient stage, significantly expanding the potential for therapeutic, high-tech interventional, and surgical care. The full diagnostic cycle for patients with pulmonary hypertension was reduced from two months to just 2–3 days. In the near future, Technigas is expected to become a standard part of the infrastructure at Pirogov Hospital.
The medical professional community has responded positively to the results of the trial, and several multidisciplinary medical centers are already working on procuring Technigas.
Technigas is considered the gold standard for pulmonary ventilation scintigraphy. When combined with perfusion imaging, it provides the highest sensitivity, specificity, and diagnostic accuracy for conditions such as pulmonary embolism (PE), chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD), bronchial asthma, complications from COVID-19, and other diseases.